1.6224
Aprea Therapeutics Inc stock is traded at $1.6224, with a volume of 22,934.
It is up +8.16% in the last 24 hours and down -28.21% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$1.50
Open:
$1.55
24h Volume:
22,934
Relative Volume:
0.86
Market Cap:
$8.15M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.4066
EPS:
-3.99
Net Cash Flow:
$-12.27M
1W Performance:
+8.13%
1M Performance:
-28.21%
6M Performance:
-58.40%
1Y Performance:
-68.62%
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
APRE
Aprea Therapeutics Inc
|
1.6224 | 8.15M | 0 | -14.29M | -12.27M | -3.99 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.47 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
599.76 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
600.51 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
242.61 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
256.16 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Dec-16-20 | Initiated | Berenberg | Buy |
Sep-29-20 | Resumed | JP Morgan | Neutral |
Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
Apr-21-20 | Initiated | Robert W. Baird | Outperform |
Oct-28-19 | Initiated | JP Morgan | Neutral |
Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MyChesCo
APRE stock touches 52-week low at $1.5 amid market challenges - Investing.com Australia
Adicet Bio Strengthens Board with Ex-Johnson & Johnson VP: Strategic Move for Cell Therapy Pioneer - Stock Titan
Aprea Therapeutics Welcomes New Chief Medical Officer to Spearhead Clinical Pipeline Expansion - MSN
Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing - MSN
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve
APRE stock touches 52-week low at $1.74 amid market challenges - Investing.com
Aprea Therapeutics CEO Gilad Oren acquires $10,110 in stock By Investing.com - Investing.com India
Aprea Therapeutics President/CEO Gilad Oren Acquires 5,500 Shares - TradingView
Aprea Therapeutics CEO Gilad Oren acquires $10,110 in stock - Investing.com
Biotech Alert: Searches spiking for these stocks today - TipRanks
Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial - Yahoo
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 28.0% in March - Defense World
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial - TradingView
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
What is Wedbush’s Estimate for APRE FY2025 Earnings? - The AM Reporter
Brokers Issue Forecasts for APRE FY2025 Earnings - Defense World
Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations - MSN
What is Wedbush’s Estimate for APRE FY2029 Earnings? - Defense World
APRE stock touches 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa
APRE stock touches 52-week low at $2.15 amid market challenges - Investing.com India
Aprea Therapeutics (NASDAQ:APRE) Given “Outperform” Rating at Wedbush - Defense World
Aprea Therapeutics Advances Cancer Trials Amid Financial Progress - TipRanks
Aprea Therapeutics repots Q4 EPS (49c) vs. (92c) last year - TipRanks
Aprea Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
APREA THERAPEUTICS Earnings Results: $APRE Reports Quarterly Earnings - Nasdaq
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - The Manila Times
Chronic Myeloid Leukemia Pipeline: Driving Innovation with 25+ - openPR.com
Windtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI - MyChesCo
Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 - MyChesCo
Aprea Therapeutics (APRE) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research - MyChesCo
MD Anderson to explore Aprea’s WEE1 kinase inhibitor for HNSCC - BioWorld Online
Aprea Therapeutics partners with MD Anderson for cancer study - Investing.com India
Aprea Therapeutics Announces Agreement With MD Anderson Cancer Center To Explore Apr-1051 As A Potential Treatment For Head And Neck Squamous Cell Carcinoma (Hnscc) - Marketscreener.com
Aprea Therapeutics partners with MD Anderson for cancer study By Investing.com - Investing.com South Africa
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) - The Manila Times
Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MSN
Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MSN
Head-To-Head Comparison: Apellis Pharmaceuticals (NASDAQ:APLS) versus Aprea Therapeutics (NASDAQ:APRE) - Defense World
Insider Buyers Lose US$92k As Aprea Therapeutics Sheds US$3.2m - Simply Wall St
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation - MSN
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):